Research Analysts’ Recent Ratings Changes for GH Research (GHRS)

GH Research (NASDAQ: GHRS) has recently received a number of price target changes and ratings updates:

• 5/19/2026 – GH Research had its price target lowered by HC Wainwright from $70.00 to $65.00. They now have a “buy” rating on the stock.
• 5/15/2026 – GH Research had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/15/2026 – GH Research had its price target raised by Cantor Fitzgerald from $25.00 to $35.00. They now have an “overweight” rating on the stock.
• 5/15/2026 – GH Research had its price target lowered by Citizens Jmp from $42.00 to $39.00. They now have a “market outperform” rating on the stock.
• 4/21/2026 – GH Research had its “sell (d-)” rating reaffirmed by Weiss Ratings.

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.